• Saniona completed required toxicology and CMC work for SAN2465, clearing the way for a US IND filing by end-October 2026.
• The company is finalizing IND documentation for submission to the FDA.
• A planned Phase 1 trial would test safety, tolerability, pharmacokinetics, and biomarkers in healthy volunteers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Saniona AB published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.